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1 INTRODUCTION 
Medication-related osteonecrosis of the jaw (MRONJ) has become a well-known side 
effect of antiresorptive and antiangiogenetic drugs. 
 
1.1 Medication-related osteonecrosis of the jaw (MRONJ): Review 
This side effect emerged in 2003 as Bisphosphonate-related osteonecrosis of the jaw 
(BRONJ). In 2014, AAOMS (American Association of Oral and Maxillofacial Surgeons) 
changed the nomenclature from BRONJ to MRONJ due to the additional use of Denosumab 
as an antiresorptive drug. Antiresorptive drugs are used to reduce skeletal-related events in 
metastatic bone disease, multiple forms of osteoporosis (juvenile, postmenopausal or senile, 
glucocorticoid-induced, transplant-induced, immobility-induced, and androgen-deprivation-
related) and heritable skeletal disorders in children [1, 2]. Osteonecrosis of the jaw (ONJ) was 
known at the beginning as “avascular necrosis of the jaw” [3]. 
MRONJ occurs worldwide especially in Europe and North America. Other particular 
side effects of antiresorptive drugs are an increased incidence of hypocalcemia, acute 
inflammatory response, musculoskeletal pain and atrial fibrillation. 
 
1.1.1 Criteria (definition) of MRONJ 
AAOMS has defined MRONJ based on patient history and on clinical findings as 
follows: 
1. Current or previous treatment with antiresorptive or anti-angiogenic agents. 
2. Exposed bone or bone that can be probed through an intraoral or extra oral fistula 
in the maxillofacial region that has persisted for more than eight weeks. 
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3. No history of radiation therapy to the jaws or obvious metastatic disease to the 
jaws [4]. 
 
1.1.1 Classification of MRONJ 
MRONJ had been classified clinically and radiographically. Table 1 & Figure 1 
represent clinical pictures and the details of AAOMS classification systems. The most 
commonly used classification is the one of AAOMS in 2014. Staging of MRONJ relies on 
clinical and radiographic examinations. It is necessary to ensure an accurate reflection of 
disease presentation and to assist in the appropriate stratification of patients. 
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Table 1: Staging system of MRONJ [4]  
Stage Clinical presentation Management 
At risk No apparent necrotic bone in patients who have been treated with either oral or 
IV bisphosphonates 
 
 No treatment 
indicated  
 Patient education 
Stage 0 
 
No clinical evidence of necrotic bone, but non-specific clinical and 
radiographic findings and symptoms such as Non-exposed bone variant 
 
Symptoms: 
 odontalgia not explained by an odontogenic cause  
 dull, aching bone pain in the body of the mandible, which may 
radiate to the temporomandibular joint region 
 sinus pain, which may be associated with inflammation and 
thickening of the maxillary sinus wall 
 altered neurosensory function 
Clinical Findings: 
 loosening of teeth not explained by chronic periodontal disease 
periapical/periodontal fistula that is not associated with pulpal 
necrosis due to caries 
Radiographic Findings:  
 alveolar bone loss or resorption not attributable to chronic 
periodontal disease  
 changes to trabecular pattern—dense woven bone and persistence of 
unremodeled bone in extraction sockets 
 regions of osteosclerosis involving the alveolar bone and/or the 
surrounding basilar bone 
 thickening/obscuring of periodontal ligament (thickening of the 
lamina dura and decreased size of the periodontal ligament space) 
 
 Systemic 
management,  
including the use of 
pain medication and 
antibiotics 
Stage 1 Exposed and necrotic bone or fistulae that probes to bone, in patients who are 
asymptomatic and have no evidence of infection.  
These patients may also present with radiographic findings mentioned for Stage 
0, which are localized to the alveolar bone region. 
 Antibacterial mouth 
rinse  
 Clinical follow-up on 
a quarterly basis  
 Patient education and 
review of indications 
for continued 
bisphosphonate 
therapy 
 
Stage 2 Exposed and necrotic bone, or fistulae that probe to bone, with evidence of 
infection as evidenced by pain and erythema in the region of the exposed bone 
with or without purulent drainage.  
These patients are typically symptomatic.  
These patients may also present with radiographic findings mentioned for Stage 
0, which are localized to the alveolar bone region. 
 
 Symptomatic 
treatment with oral 
antibiotics, Oral 
antibacterial mouth 
rinse 
 Pain control  
 Debridement to 
relieve soft tissue 
irritation and 
infection control 
Stage 3 Exposed and necrotic bone, or fistulae that probe to bone, with evidence of 
infection, and one or more of the following:  
 exposed necrotic bone extending beyond the region of alveolar bone, 
i.e., inferior border and ramus in the mandible, maxillary sinus and 
zygoma in the maxilla pathologic fracture • extra-oral fistula  
 oral antral/oral nasal communication  
 osteolysis extending to the inferior border of the mandible or sinus 
floor 
 
 Antibacterial mouth 
rinse  
 Antibiotic therapy 
and pain control  
 Surgical 
debridement/resection 
for longer term 
palliation of infection 
and pain 
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Figure 1: (Upper left and right) Clinical presentation of stage 0 MRONJ and necrotic bone sample from surgery. 
(Lower left and right) Clinical presentation of stage 2 MRONJ and necrotic bone sample. 
 
 
1.1.2 Antiresorptive medications 
Bisphosphonates are chemical derivatives of inorganic pyrophosphate (PPi) which are 
capable of binding to hydroxyapatite crystals like natural PPi. Bisphosphonates preferably 
incorporate into active bone remodelling sites, they inhibit hydroxyapatite breakdown, 
thereby effectively suppressing bone resorption [2, 6]. 
They can be divided structurally into nitrogen containing bisphosphonates (NBPs) and 
non-nitrogen containing bisphosphonates (non-NBPs) by the presence or the absence of an 
amino functional group in the molecule (Figure 2). NBPs are much more potent when 
compared to non-NBPs which were widely used in previous decades. The class of 
bisphosphonates, indication, dose / administration and their trade names are presented in 
Appendix 1. 
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Figure 2: Bisphosphonate structures and approximate relative potencies for osteoclast inhibition [2]  ]. 
 
 
Bisphosphonates can be administered either intravenously or orally. Intravenous 
bisphosphonates (BPs) are widely used mainly to regulate skeletal-related events (SRE) 
correlated with bone metastasis in advanced solid tumours and bone lytic lesions of multiple 
myeloma and also in patients with osteoporosis. Oral bisphosphonates are mainly use to 
manage osteoporosis, osteopenia and other conditions such as Paget’s disease and 
osteogenesis imperfecta [7, 8]. 
Denosumab is the most recent antiresortive drug used which is a human monoclonal 
antibody that specifically binds to receptor activator of the nuclear factor kappa-B ligand 
(RANKL) inhibiting osteoclast function and bone resorption. Denosumab is different when 
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compared to the bisphosphonates having a shortened half-life. The effect on bone remodelling 
will decrease after 6 months of drug cessation and an inhibition will resolve within 1 year [9]. 
It is important to mention that MRONJ does not occur only due to the use of 
antiresorptive drugs (Bisphosphonates and Denosumab) but also due to the use of 
antiangiogenetic drugs which can be divided into two subgroups: Monoclonal antibodies that 
block receptor or growth factor (bevacizumab) and small molecules that bind to tyrosine 
kinase receptor (sunitinib and sorafenib) [4]. 
Antiangiogenic medication acts by suppressing new blood vessels formation by 
blocking the angiogenesis-signalling cascade. They are beneficial in the treatment of 
gastrointestinal-, neuroendocrine tumours and renal cell carcinomas [4]. 
 
1.2 Pathophysiology of MRONJ 
This disease has not been fully elucidated [9, 10]. 
1.2.1 Hypotheses being proposed for MRONJ [4] 
Several hypotheses were proposed to explain why antiresorptive drugs cause MRONJ 
almost exclusively in the jaw bone: a) altered bone remodelling and induced osteoclasts 
apoptosis, b) angiogenesis inhibition, c) tissue toxicity, d) immune dysfunction, e) infection or 
inflammation. Each theory is explained in details as follows: 
 
a. Decrease of bone turnover by inhibition of osteoclast function: 
bisphosphonates and denosumab suppress osteoclast function leading to a 
reduction of bone remodelling that could cause osteonecrosis [11, 12, 13, 14]. 
Nitrogen-containing bisphosphonates act intracellularly by inhibiting farnesyl 
diphosphate synthase, which is needed in normal cellular function. 
Bisphosphonates are highly effective inhibitors of bone resorption that 
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selectively affect osteoclasts and also have direct effects on other cell types 
[11]. 
Denosumab binds to RANKL, preventing the maturation and differentiation of 
preosteoclasts and promotes apoptosis of osteoclasts. Bone resorption is 
therefore slowed [15]. 
b. Inhibition of angiogenesis: interruption of blood supply is one of a main causes 
of osteonecrosis [17, 18, 19]. Zoledronate can have antiangiogenic effects by 
inhibiting vascular endothelial cell growth factor proliferations. 
Bisphosphonates also reduce endothelial progenitor cell colony formation and 
migration (in vitro), thereby disturbing neovascularisation [20, 21]. By 
suppressing osseous angiogenesis and bone remodelling, bisphosphonates 
actualise bone necrosis in mice [22, 23]. 
c. Local toxicity: soft and hard tissue toxicity can lead to non-healing, exposed 
lesions in MORNJ [24, 25]. 
Apart from reducing osteoclasts activity bisphosphonates reduce the biological 
activity and viability of osteoblasts, epithelial cell, keratinocytes and fibroblast 
additionally. Moreover, the accumulation of bisphosphonates in tissue could 
cause direct toxicity to the oral epithelium and subcutaneous tissue. After an 
injury bisphosphonates are responsible for the delayed oral keratinocyte wound 
healing process. This could explain the high frequency of bone exposing 
lesions and delayed or unhealed wounds which turn into osteonecrosis lesions 
[26, 27]. 
d. Immunomodulation: antiresorptive drugs can modulate the activity of various 
cell types in human immune mechanism. 
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There is evidence that the cellular immune system (monocytes/macrophages, 
neutrophils and T-cell function) is suppressed by bisphosphonates (BPs). This 
could alleviate the response towards infection process [28, 29]. 
e. Infection and inflammation: Inflammation has sustained as an important 
component of MRONJ. 
 
1.2.2 Infection & inflammation hypothesis 
MRONJ is presented clinically as necrotic bone that can be accompanied by pain, 
swelling, soft tissue inflammation, pus exsudation, and or intra-/extraoral fistula. Antibiotics 
and antimicrobial control are normally recommended for MRONJ treatment. It commonly 
implies that an infectious component is generally involved in MRONJ development [4, 29, 
30]. 
In vitro, bisphosphonates are reported to intensify adhesion of bacteria to 
hydroxyapatite and boost the rate of biofilm formation [31, 32]. It was found that microbial 
colonization in MRONJ cases was significantly greater than in bone necrosis in the absence of 
BPs, raising the possibility that BPs could increase bacterial and biofilm accumulation [33]. 
Moreover, immune response in MRONJ patients had been altered creating a negative 
environment that benefits opportunistic pathogens (Parvimonas, Peptostreptpcoccus, 
Fusobacterium, Eubacterium, Dialister and Gemella) [34]. It was found in animal models that 
bacterial stimulation could create MRONJ-like lesion in mice bone [35, 36]. 
One of the convincing arguments was that BPs would be released from the bone in an 
acidic environment (low pH value). In an inflammatory situation, BPs will slow an immune 
response which allows an infection to persist in the lesion, at the same time pathogens assist 
in creating an accumulation of BPs and toxin [37, 38]. This vicious cycle together with other 
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negative effect (bone turnover suppression, immunomodulation, tissue toxicity and 
avascularisation) may amplify a necrotic process of the jaw. 
Therefore, infection is one of the most possible causes and an important factor 
developing osteonecrosis. However, the most reasonable answer could be that MRONJ occurs 
under a combination of all the above theories [39]. We considered the infection to be an 
important initiating factor. 
 
1.3 Comorbidities, Risk and Local Factors of MRONJ 
MRONJ is thought to be influenced by multiple factors [40]. Aniresorptive medication 
itself is considered as a primary risk factor including type (drug classification, potency & half-
life), dose, frequency and the route of administration. Zoledronate has the highest potency in 
BPs and is related to more than 40% of MRONJ cases [41, 52]. High doses of intravenous 
bisphosphonates given in oncological condition were related to 94% of MRONJ cases which 
are much different in the oral bisphosphonates group [42]. The duration of the substance 
exposure was also claimed to be an important factor in MRONJ [41]. 
However, besides the antiresorptive drug itself several risk factors were published in 
previous studies [41]. Chemotherapy, Corticosteroids and co-morbid conditions such as 
anaemia and diabetes were reported to be correlated with an increased risk of MRONJ [43, 
44, 45]. Chemotherapy drugs worsen MRONJ-like lesions in an animal model [22]. Smoking 
was also significantly associated with MRONJ development [46, 47]. Vitamin D deficiency 
shows a significant increasing incident rate of osteonecrosis in rats by dysregulated bone 
homeostasis and innate immunity [48]. Thalidomide, an immunomodulatory agent used in 
multiple myeloma patients could also aggravate early-stage MRONJ and may attribute disease 
progression to the jaw by inhibiting angiogenesis [49]. 
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Trauma in form of tooth extraction is often mentioned as a preceding event of 
MRONJ. Preceding events such’s long-term NBPs therapy and recent dental procedures are 
consistent findings in patients with MRONJ [50]; tooth extraction having the most negative 
influence in MRONJ staging [51]. Tooth extraction was reported in up to 60% of MRONJ 
cases [52, 54]. 
 
1.4 Evidence supporting infection theory: Is it trauma that triggers 
ONJ or pre-existing infection conditions?  
Around 25% of MRONJ cases occur spontaneously [52, 53]. There is more stage 0 
ONJ recently. Stage 0 category was added in 2009 AAOMS MRONJ-classification to include 
patients with non-specific symptoms, or clinical and radiographic abnormalities that may be 
due to the exposure to an antiresorptive agents [5]. In 2008, Junquera and Gallego presented 
two cases of this pathology without this clinical condition [56]. In 2010 Hutchinson, et al. had 
stage 0 disease with similar radiographic features of osteosclerosis in clinically symptomatic 
areas, most with an extension beyond the involved site [57]. In 2014, Aghaloo et al. also 
reported cases of stage 0 MRONJ in patients on denosumab and indicated the full-spectrum of 
similarities between BP- and denosumab-associated MRONJ clinically, radiographically, and 
histologically [58]. In our hospital (Department of oral and maxillofacial surgery, LMU), we 
found a stage 0 MRONJ patient which was treated conservatively and had a positive clinical 
response. Disease regression in radiological finding was also observed. This finding implies 
non-traumatizing MRONJ and should be further investigated. 
MRONJ incidence is usually related to dental procedures and these are often 
performed in septic environment due to dental infection. Tooth extractions were performed in 
most of the previous reported cases of MRONJ. However, these teeth commonly had existing 
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periapical or periodontal diseases [5, 52, 60, 61]. In 2015, Ikeda T., et al. report successful 
Stage 0 MRONJ case treated with antibiotics alone [59]. 
Local infection together with tooth extraction can create a negative environment 
affecting MRONJ. At the same time, infection alone without micro trauma could cause 
spontaneous and stage 0 ONJ cases. We questioned if it is not tooth extraction itself, but 
rather prevailing infectious conditions that may be a key risk factor for the development of 
MRONJ [62]. 
 
1.5 Histopathological findings in MRONJ: infection & inflammation 
pictures are familiar 
A diagnostic biopsy is often not performed in patient with MRONJ lesion because of 
possible wound healing disturbances. Pathological investigation normally has a role in 
confirming clinical diagnosis after surgery [28, 116]. 
Microscopic images of MRONJ were normally presented with necrotic bone with 
irregular peripheral resorption and often surrounded by bacterial colonies [63]. The empty 
Howship lacunae at a peripheral area display an osteoclast’s apoptotic figure [64]. 
Intertrabecular spaces were infiltrated with inflammatory cells such as neutrophils, 
lymphocytes and plasma cells [65, 66, 67]. 
Filamentous form bacteria and focal acute inflammation were found [68, 68]. 
Actinomyces are one of a common microorganisms in histological findings [70, 71, 72, 73]. 
Infection impression and bacterial accumulation are typically shown in Histological-
pathological reports. 
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1.6 Previous microbiological study of MRONJ 
Seven hundred and fifty different bacterial species were found in the oral cavity [74]. 
A microbial biofilm is a community of microorganisms attached to a surface and surrounded 
by a matrix of extracellular polymeric substance [75]. Biofilm organisms are embedded in a 
matrix of extracellular polymeric substances that they have produced in order to connect to 
and communicate with each other, and exhibit an altered phenotype in terms of growth rate, 
gene transcription and antimicrobial resistance [76, 77]. 
Polymicrobial infection and periodontal disease may contribute to development of 
MRONJ as a biofilm associated infection [78]. Infection of the denuded bone and the creation 
of a biofilm composed of gram-positive and gram-negative strains and anaerobes have been 
documented [79]. 
 
1.6.1 Microorganism identification of MRONJ 
In previous studies, gram-positive and negative organisms have been reported in 
biofilms of MRONJ patients. Aerobes, anaerobes and facultative anaerobes were found [79]. 
Common species were Genus Fusobacterial, Bacillus, Actinomyces, Staphylococcus, 
Streptococcus, Selenomonas and Treponemes. Candida species were also observed in almost 
all of the samples. Anaerobes showed a dominant role, suggesting an inhibited angiogenesis 
in MRONJ [79]. 
There were not many previous microbiological reports from bone sample biopsies. 
One control-cohort study with molecular bacterial identification (from 15 samples) showed a 
significant difference in bacterial genera between MRONJ bone samples and control groups. 
Parvimonas, Peptostreptococcus, Fusobacterium, Eubacterium, Dialister and Gemella were 
reported [34]. In another study, 12 infected bone samples (6-MRONJ and 6 normal infected 
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bone) culture and molecular profiling reported that Streptococcus, Eubacterium, and 
Pseudoramibacter were peculiar to MRONJ lesions compared to normal infected bone [30]. 
All previous studies had the same limitation of a small subject number of culture 
samples which lead to our study objective. 
 
1.7 Actinomyces finding in MRONJ 
Actinomyces are gram-positive pleomorphic, anaerobic to microaerophilic, 
filamentous, non-motile, non-spore-forming bacteria that can be found in calculus, 
periodontal pockets, carious lesions and oral mucosal surfaces, in addition to the upper 
respiratory, gastrointestinal tracts and female genital mucosa [80, 81, 82]. 
 
1.7.1 Characteristics of Actinomyces 
Actinomyces are one of the dominating genera in the oral cavity. At least 25 species 
have currently been published of human specimen and 8 (A. gorgiae, A. gerencseriae, A. 
gravenitzii, A. israellii, A. meyeri, A. naeslundii, A. odontolyticus and A. oris) of them from 
the oral cavity [83]. Orocervicofacial actinomycosis is the most common actinomycosis 
which was found in more than 50% of all cases [84, 85]. Actinomyces species are mainly 
associated not only with cervicofacial actinomycosis but also with oral or cerebral abscesses, 
dental caries and periodontitis [86, 87]. They also seem to play a greater role than expected in 
the pathogenesis of osteoradionecrosis and MRONJ. 
Actinomyces do not cause disease as long as they stay on the surface of the mucosa. 
However, if the integrity of the mucosal barrier is compromised and the bacteria gain access 
to the oral tissues or jaw bone, they may initiate a prolonged chronic inflammatory process, 
creating a tumour-like mass, tissue destruction, osteolysis, and multiple sinus tracts named 
“Actinomycosis” [86]. 
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1.7.2 Actinomyces with MRONJ 
Actinomyces are one of the most common findings in many MRONJ microbial reports 
[70, 88, 89, 90, 91]. A report found a significant symptoms improvement in MRONJ 
(symptoms free) after Actinomyces treatment with antibiotic [80]. 
There are histopathological reports among osteoradionecrosis and MRONJ patients, 
showing direct association of actinomyces colonies with bone lesions. The filamentous, 
anaerobe actinomyces has long been associated with the necrotic bone found in MRONJ 
lesions, but the exact role of the bacteria is still unclear [92, 93]. One report found up to 90% 
(9/10) positive finding of actinomyces accumulation in bone sample biopsy of MRONJ [94]. 
 
1.7.3 Actinomyces identification: Conventional culture vs Gene sequence 
analysis 
It is unreliable and challenging to identify Actinomyces with conservative methods 
[93]. Actinomyces identification is possible under microscopic investigation. At present with 
gram-positive branching filamentous organisms. However, results should be interpreted 
cautiously with a relevant clinical history, signs and symptoms [83]. 
Actinomyces culture needs 48 hours of incubation period or longer under anaerobic 
conditions and the definitive identification may take 2-3 weeks [81]. Most actinomyces 
species could be identified using conventional biochemical tests but this is still challenging 
[94]. Indifferent growth in media frequently lead to false-negative actinomyces culture results 
and poor reproducibility. To date, it is recognized that it may result in misidentification of 
clinical isolates of Actinomyces by using conventional and biochemical test. 
16S rRNA gene sequence analysis, which was originally used to reconstruct an 
organism phylogenetic relationship, is in recent years an alternative method. It can provide far 
more precise identification [83, 95]. 
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To differentiate from culture method, gene sequencing with PCR has more sensibility 
because of the amplification ability with high fidelity. The ability to detect non-vital genetic 
substance from specimen and amplifying was the advantage in this method [93]. In 2013, 
Kaya D, et al. compared PCR with culturing and microscopic identification for accurate 
diagnosis of genital actinomyces. This study shows that PCR is the most sensible and reliable 
detection method. 
Some previous studies refused actinomyces signification by finding MRONJ lesions 
without actinomyces infection [55]. However, we believe that there is still a detection missing 
of actinomyces in conventional methods.  
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1.8 Study Proposes 
The main objectives of this thesis are: 
1. To identify the bacterial profile in MRONJ bone samples from culture 
reports. 
2. To confirm the involvement of actinomyces in the infectious aspect of 
MRONJ by using PCR. 
3. To add more information on MRONJ characteristics as well as risk factors for 
developing MRONJ.  
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2 MATERIALS AND METHODS 
2.1 Study population and Setting 
This study was a single centre retrospective study carried out at the oral and 
maxillofacial surgery department, Ludwig-Maximillians-University, Munich, Germany to 
identify all patients with MRONJ from January 2003 to December 2015. Ethic Votum nr: 
145-16 
 
2.1.1 Inclusion & Exclusion criteria 
2.1.1.1 Inclusion Criteria 
i) MRONJ patients were diagnosed based on AAOMS position paper [4]. 
a. Current or previous treatment with antiresorptive or antiangiogenic 
agents. 
b. Exposed bone or bone that can be probed through an intraoral or 
extraoral fistula(e) in the maxillofacial region that has persisted for 
more than eight weeks. 
c. No history of radiation therapy to the jaws or obvious metastatic 
disease to the jaws. 
ii) MRONJ patients with microbiological examination. 
 
2.1.1.2 Exclusion Criteria 
To minimize confounding variables or effect modifiers, i) patients missing clinical, 
radiographic, or follow-up data; ii) if they had a history of head and neck radiation as this can 
cause osteonecrosis unrelated to antiresorptive drugs; iii) missing information or 
inappropriate microbiological technique 
18 
 
 
To validate culture results and minimize technique variation, according to our expert 
consultant opinion, we excluded all samples with: i) different culture technique (only bone 
sample biopsy accepted) and ii) all reports before 2008 (due to different culturing technique 
and microorganism identifying index).  
 
2.2 Data collection  
Patient’s records were screened and a separate data sheet was designed to be filled out 
with the information for each included patient. With a detailed history concerning clinical 
presentation: age, sex, location of the lesion, primary cause of antiresorptive treatment, 
comorbidities, clinical presentation, MRONJ clinical staging, the type of antiresorptive drug, 
the route of administration, the treatment course, the pathological findings of bone specimens 
obtained from surgeries.  
All cases underwent radiographic evaluation with at least panoramic radiograph to rule 
out other aetiologies of jaw necrosis before surgical intervention. Surgery was performed only 
in patients with good general health status. Antiresorptive therapy was not generally 
interrupted during and after the surgical procedure unless the oncologist believed the patient 
needed a break as part of the cancer drug therapy (individual decision after discussion with an 
oncologist). All surgical procedures took place in the same unit. 
 Bone samples were collected and sent for pathological, microbiological investigation 
and PCR (for actinomyces, if possible). One sample of bone from each patient affected by 
MRONJ in our study was cut into sub fragments and i) send for pathological examination to 
confirm MRONJ diagnosis and to look for signs of ongoing infection & inflammation. ii) 
prepared for microbiological analysis as described below. 
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2.3 Microbiological Study 
A collaboration was done between the oral and maxillofacial department (Head: Prof. 
Dr.Dr. Michael Ehrenfeld) and Max-von Pattenkofer Institute of Microbiology directed by 
Prof. Dr. Sören Schubert, Grosshaden, Munich. All the microbiological tests were performed 
in the same lab. 
 
2.4 Identification process 
Classical bacterial diagnostics were used for the bone samples. For this, aerobic 
cultures were prepared on Columbia blood-agar, MacConckey-agar and Columbia-CAN-agar, 
anaerobic cultures on Schaedler-agar and Schaedler-KV-agar (all agar plates from BD, 
Heidelberg, Germany). Besides, the swabs were cultivated in thioglycolate broth. All aerobe 
cultures have been read after 24h, 48h and 72h, the anaerobic cultures after 2d, 5d and 7d. The 
bacterial counts have been enumerated semi-quantitative and bacterial colonies were objected 
to MALDI-TOF MS for further species identification. 
 Samples were evaluated by the use of Microflex LT mass spectrometer (Bruker 
Daltonik GmbH, Bremen, Germany) in linear positive-ion mode across the m/z range of 2,000 
to 20,000 Da. Each spot was measured by using 240 laser shots at 60 Hz in groups of 40 shots 
per sampling area of the spot. Spectra were analyzed by using MALDI Biotyper software (v 
3.1 – Build 65). Sample preparation included either the “direct transfer method”, the 
“Extended Direct Transfer method (EDT)” or the “ethanol/formic acid extract method” as 
previously described [17]. Resulting spectra were compared against reference spectra using 
Bruker MALDI-TOF Biotyper software to obtain identification with a confidence score. For 
most isolates, the MSP (Main Spectral Projection) reference spectra were those contained in 
the Bruker database of 2013 (database version V 3.3.1.2) containing 364 genera, 2185 species 
and 4613 individual MSP. Results with score >2 were considered as correct species 
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identification, results displaying values of 1.5≤ and ≤2 were accepted as correct genus 
identification. 
 Identification of bacteria by sequencing of 16S rDNA has been performed as described 
previously with some modifications [18]. In brief, crude bacterial lysates were prepared 
directly from culture plates by suspending bacteria from a clonal culture in 100 μl of RT-PCR 
grade water (approximately McFarland Standard 2.0) and placed in a hot block at 100 °C for 
10 min. A ~800 bp-fragment of 16S rDNA was amplified using the universal primer pair FD1 
5′-AGAGTTTGATCCTGGCTCAG-3′ and 800r 5′-GAGTACCAGGGTATCTAATCC-3′. 
Resulting PCR amplicons were sequenced using the same primers and standard sequencing 
methods. Data from both strands were aligned in SeqMan (DNASTAR Lasergene 8 Suite) to 
generate a contig of around 800 bp. The consensus sequences were then used to compare with 
online databases (NCBI BLAST—http://blast.ncbi.nlm.nih.gov/Blast.cgi) and the Ribosomal 
Database Project (http://rdp.cme.msu.edu/). Identification criteria of 99% sequence identity 
for identification to species level were applied [19], where matches had to be to the species 
type strain. The identities of type strains, as well as accession numbers in NCBI for equivalent 
16S rDNA sequences, are available at http://www.bacterio.cict.fr/ for all validly published 
bacterial species. 
 According to the suggestion of our experienced microbiologist (Prof. Schubert), 
Species from culture results were grouped into 14 categories: 
1 = Actinomyces sp.    2 = Bacteroides sp. 
3 = Enterobacter gr.    4 = Fusobacterium sp. 
5 = Prevotella sp.    6 = Streptococcus gr. 
7 = Enterococcus sp.    8 = Candida sp. 
9 = Haemophilus sp.    10 = Neisseria sp. 
11 = Porphyromonas sp.   12 = Veillonella sp. 
13 = Mixed flora of oral cavity  14 = Miscellaneous 
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Due to high likelihood of false positive culture from environmental exposure, we 
considered only at least strongly positive +2 culture result as positive culture [positive (+1) 
and mild positive (+) will be excluded]. 
Bacteria profiling was done also in a small group to see if it has a different outcome in 
culture results (Sub group analysis) such as: 
 swap culture vs bone culture 
 patients with chemotherapy vs without chemotherapy 
 patiens with tobacco use vs non-tobacco group 
From pathological finding, we were looking not only for dead bone to confirm 
MRONJ diagnosis but also for signs of infection & inflammation such as inflammatory cell 
infiltration, bacterial colonization and specifically presentation of filamentous forming 
bacteria (Actinomyces). This investigation was done to enhance the value of bacterial 
profiling by confirming active infection in bone samples. 
 
2.5 Statistical analysis 
Statistical analysis was performed using SPSS version 22.0 (SPSS Inc., Chicago, IL, 
USA). Results are expressed as mean values including standard error of the mean and range. 
Means were compared by statistical testing (Student's t-test), where p < 0.05 was considered 
to be significant. 
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3 RESULTS 
3.1 Descriptive study: Risk assessment in MRONJ patients 
The medical and dental records of 209 patients diagnosed with MRONJ and evaluated 
with microbiological investigation, from first of January 2003 till the end of December 2015, 
were reviewed. Of those patients, 136 patients fulfilled the inclusion criteria and were 
included in this thesis (see Figure 3). 
  
Figure 3: Patient selection flowchart  
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3.1.1 Patients Characteristics 
The demographic characteristics of these patients were summarized as below (Total 
n=136). 
3.1.1.1 Age & Gender 
The mean age of the patients was 70.1 years± 8.83 SD; 53 (39 %) of the patients were 
males and 83 (61%) were female. The mean age of both genders were similar (male 71.2 and 
female 69.4). 
 
 
Figure 4: Age & Sex distribution 
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3.2 Cause of antiresorptive treatment 
Breast cancer was the most called cause for the administration of antiresorptive drugs 
n=50 (36.8%), followed by prostate cancer n=31 (22.8%) and multiple myeloma n=17 
(12.5%). The remainder were diagnosed with osteoporosis n=18 (13.2%) and lung cancer n=4 
(2.9%). 
Most of the female patients had breast cancer (59%) while prostate cancer was most 
common in male patients (58.4%).  
 
Table 2: Cause of antiresorptive drugs treatment 
Cause of ARD male female total, n (%) 
Breast cancer 1 49 50 (36.8) 
Prostate cancer 31 0 31 (22.8) 
Multiple myeloma 8 9 17 (12.5) 
Osteoporosis 3 15 18 (13.2) 
Lung cancer 3 1 4 (2.9) 
 
Other causes included: colon cancer, systemic mastocytosis, renal cancer, CUO 
(cancer with unknown origin), bladder cancer, thyroid cancer, endometrium cancer make up 
11.7% (16 from 136) of all samples. 
 
 
3.2.1 Antiresorptive agents 
Among the ARD groups, the largest population 71 (52.2%) received zoledronate 
alone, 5 (3.7%) received pamidronate alone, 5 (3.7%) received ibandronate, 38 (27.9%) 
received combination of BPs and 17 (12.5%) received denosumab. 
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Figure 5: Distribution of the various antiresorptive drugs (in percent) 
 
3.2.1.1 Application form of Antiresorptive drugs (ARD) 
Most of the patients, 110 (80.9%) received intravenous ARD, 9 (6.6%) received oral form and 
17(12.5%) received subcutaneous injections. 
 
 
Figure 6: Route of drug administration (in percent) 
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3.3 Localization 
 Most of the patients had lesions in the mandible. 58% in the mandible alone, 15% had 
lesion in both jaws and 26.5% in the maxilla alone. 39% of patients had lesions located on 
right side only, while 36% of patients had lesions on the left side only and around 24% had 
lesions on both sides. 
 
 
 
Figure 7: Distribution of MRONJ lesion. Localisation in FDI two-digit tooth numbering system 
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3.4 Comorbidities 
 The relevant comorbidities, identified in 136 patients, included diabetes mellitus 
(n=26, 19.1%), chemotherapy (n=80, 58.8%), history receiving body irradiation (apart from 
head and neck radiation) (n=61, 44.9%). 
 Thirty three patients received steroid treatment (24.3%) and 3(2.3%) received 
immunomodulation drugs (thalidomide). 
 Thirty eight patients report of past smoking habits (27.9%) and 21 from 38 were still 
smoking (15.4). 
 
Table 3: Summary of comorbidities 
Comorbidities n(%) 
Metastatic bone 92 (67.6) 
Other skeletal disease 21 (15.4) 
Diabetes 26 (19.1) 
Cardio vascular disease 47 (34.6) 
metastasis in organs 38 (27.9) 
Hx of Chemotherapy 80 (58.8) 
Hx of Body radiation 61 (44.9) 
history of steroid intake 33 (24.3) 
Thalidomide  3 (2.3) 
 
 
Table 4: Smoking habits 
Smoking habits n(%) 
no smokers 98(72.1) 
used to smoke 17(12.5) 
still smoking 21(15.4) 
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3.5 Prevention & Prophylaxis 
 We could prove that 3% of patients had visited a dentist or an oral surgeon before 
receiving antiresorptive drugs. After diagnosis as MRONJ most of the patients (82.3%) 
stopped antiresorptive drugs permanently (25.7%) or temporary (56.6%) and 17.6% of 
patients could not. 
 
Table 5: Dental professional visited before antiresorptive therapy  
Visited before antiresorptive therapy  n(%) 
yes 4(2.9%) 
no 132 (97.1%) 
Break from antiresorptive drugs  n(%) 
never 24(17.6) 
permanent 35(25.7) 
temporary 77(56.6) 
 
 
3.6 Staging of MRONJ 
 The patients were stratified into categories according to the known antecedents or 
spontaneous development of MRONJ as in Table 1. 
 Only one case referred to stage 0 with no bone exposure but uncharacteristic signs and 
symptoms of MRONJ. 22 cases were categorized as stage 1 where bone was exposed in the 
absence of pain and signs of infection. The majority of cases (n = 82) were classified as stage 
2 based on exposed necrotic bone in the maxillofacial region accompanied by pain or signs of 
infection. 31 cases were stage 3 lesions due to complications such as pathological fracture, 
extraoral fistula formation, extension of the lesion to the inferior border of the mandible or to 
the floor of the maxillary sinus. 
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Figure 8: Staging of MRONJ lesion 
 
 
3.6.1 Clinical presentation 
 The clinical signs of MRONJ could start from burning sensation (stage 0) to silently 
exposed bone lesion (stage 1) to mandibular pathologic fracture (stage 3). Most of the patients 
presented with MRONJ in the mandible and 21 patients had involvement of the maxilla and 
mandible. 
 Regarding the onset of MRONJ, the initial symptom was inflammation in 84 patients 
(61.8%), pain in 108 patients (79.4%) and visible exposed bone in 106 patients (77.9%). Signs 
and symptoms that also occurred were: disturbances in wound healing in 86 patients (63.2%), 
suppuration in 64 patients (47.1%), pathological fracture in 12 patients (8.8%), intra-and 
extraoral swelling in 77 patients (56.6%) and fistula formation in 46 patients (33.8%).  
Eleven from 100 Mandible lesions showed inferior alveolar nerve involvement also 18 
maxillary sinus involvement from 57 maxillary lesions. 
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Table 6: Summary of patient clinical presentations 
Clinical presentation  n(%) 
Visible exposed bone 106 (77.9) 
Pain during the course 108 (79.4) 
Disturbances in wound healing 86 (63.2) 
Signs of local inflammation 84 (61.8) 
Pus presentation 64 (47.1) 
Pathological fracture 12 (8.8) 
intra- or extraoral swelling 77 (56.6) 
intra- or extraoral fistula 46 (33.8) 
Clinical presentation n(%) 
Maxilla-sinus involvement 
(from 57 Maxilla lesion) 
18 of 57 (13.2) 
Mandbular N. sensibility disturbance 
(from 100 Mandible lesion) 
11 of 100 (8.1) 
 
 
3.6.2 Preceding events 
 Relevant preceding events were tooth extractions in (n=73, 53.7%) of the lesions 
involved and (n=16, 11.8%) of the patients that underwent other dentoalveolar surgery. (n=16, 
11.8%) received periodontal treatment and (n=6, 4.4%) of the patients had denture pressure 
sores. Around 18.4% had no intervention in the lesion area. 
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Table 7: Preceding events before an onset of MRONJ 
preceding events  n(%) 
extractions 73 (53.7) 
dentoalveolar surgery  16 (11.8) 
periodontal lesion & treatment 16 (11.8) 
denture sore 6 (4.4) 
spontaneous 25 (18.4) 
 
 
3.7 Pathological Findings 
 The pathological report for all patients (n=136) was in accordance with pre-operative 
diagnosis of MRONJ. Almost all (98%) showed necrotic bone pattern and 94% presented 
inflammatory processes: neutrophils, lymphocytes or plasma cells infiltration. 
 Around three-fourth (n=101,74.3%) of the samples showed bacterial colonization and 
33% showed filamentous form rod shape bacteria which suggested actinomyces species. 
 
Table 8: Summary of pathological finding 
finding (total n = 136) n(%) 
necrotic bone 133 (97.8) 
inflammatory process 127 (93.7) 
bacterial clumping 101 (74.3) 
Actinomycess like bacteria 46 (33.8) 
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3.8 Microbiological findings 
 One hundred and fifty-five patients had either bone or swap culture. One hundred and 
eleven patients had at least one microorganism strong positive finding. Sixty-nine different 
species were found. (Appendix 2) 
 
 
Figure 9: Anaerobic bacterial culture of a MRONJ sample. Actinomyces sp. grown as large whitish colonies are 
indicated by an arrow. 
 
 In this study we focused only bone sample culturing for microorganism (swap culture 
would be excluded) in which we had one hundred and thirty-six samples. Based on bone 
culture results, around 68% of the samples had positive microbiological findings (In our 
study, we count more than highly positive [3+ and 2+] as a positive result.) and we found 
around 1.25 positive Bacteria per sample (mean 1.25, SD=1.153). The most common 
microorganisms were mixed flora of the oral cavity (30.1%) followed by actinomyces 
(21.3%), streptococcus (16.9%), enterobacter group (15.4%) and miscellaneous group 
(13.2%). 
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Figure 10: Microbiological profiling from bone cultures. Percentage of positive population (n = 136) 
 
 
3.9 Small group comparison 
 Bacteria Profiling will be done in a small group to see if it has a different outcome in 
culture results. 
 
3.9.1 Swap Group. 
 To eliminate an error due to different culture techniques we excluded a patient with 
swap test from the major sample group. Nevertheless we still have the results for small group 
comparison. The results showed five most common microorganism from the swap group: 
mixed flora of oral cavity, streptococcus, actinomyces, haemophilus and miscellaneous group. 
Haemopilus species presented instead of enterobacter group in bone culture report. 
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Figure 11: Microbiological bone culture profiling. Comparison between Swap culture gr. and Bone culture gr. 
 
 
3.9.2 Chemotherapy Group 
 We divided patients in two groups with or without chemotherapy in order to see the 
difference in the profiling. Both groups presented mixed flora of the oral cavity followed by 
actinomyces, streptococcus, enterobacter group and miscellaneous group as a most common 
organism. However, chemo gr. shows numbers of candida species (13.9%) when non-chemo 
gr. has only (7.1%). 
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Figure 12: Microbiological bone culture profiling. Comparison between Non-Chemo gr. and Chemo gr. 
 
 
3.9.3 Smoking group 
 Both patients groups with and without smoking habits show that mixed flora of oral 
cavity actinomyces, streptococcus and enterobacter group is the predominant group as is in 
the bone culture group. 
 Prevotella and enterococcus were absent in smoking gr. and candida spp. is more 
presented compare to non-smoking group (18% in smoking gr. and 8% in non-smoking gr.). 
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Figure 13: Microbiological bone culture profiling. Comparison between Non-smoking gr. and Smoking gr. 
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3.9.4 Steroid Group and Diabetes Group 
 There is not much difference in bacterial profiling of steroid and diabetes group. 
 
Patient with and without steroid treatment. 
 
Figure 14: Microbiological bone culture profiling. Comparison between Non-steroid gr. VS Steroid gr. 
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Patient with and without diabetes.  
 
Figure 15: Microbiological bone culture profiling. Comparison between Non-diabetes gr. and Diabetes gr. 
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3.10 Actinomyces identification 
 Detection of Actinomyces sp. using a specific real-time PCR was performed on 83 
patients (with the same specimen for bone cultures) and all were positive in some level. Fig 
16 represents the results of 3 positive samples with distinct cycle threshold (Ct)-values 
indicating different numbers of Actinomyces sp. in the respective patient samples. 
 
 
Figure 16: Detection of Actinomyces sp. using a specific real-time PCR. The diagram shows the results of 
positive samples with distinct cycle threshold (Ct)-values indicating different numbers of Actinomyces sp. in the 
respective patient samples. 
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Figure 17: Actinomyces findings from real time PCR 
  
 
3.10.1 Culturing vs PCR 
 In order to eliminate false positive results, we counted none of mild positive (+) and 
positive + PCR results and calculated them as negative findings similar to bone culture 
results. 
 Eighty-three patients had both bone culture and PCR for actinomyces results. Sixty of 
eighty three (72.3%) PCR test were positive while twenty three of eighty three (27.7%) had 
positive actinomyces culture results. 
 Twenty one of eighty three (25.3%) had both PCR and culture positive for 
actinomyces and thirty nine of eighty three (46.9%) had positive PCR but negative culture for 
actinomyces. 
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Table 9: Cross table defining Actinomyces finding between bone cultures and real time PCR 
Culture for Act. 
PCR for Act. 
total 
positive negative 
positive 21 2 23 
negative 39 21 60 
total 60 23 83 
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4 DISCUSSION 
The objectives of this study were i) to identify microorganisms in MRONJ from bone 
sample biopsy, ii) focusing on Actinomyces detection by performing real time PCR, and iii) 
to investigate the clinical and anamnestic characteristics in the respective MRONJ patients. 
 
4.1 Pathological-Microbiological study of MRONJ 
4.1.1 Pathophysiology  
The terminology MRONJ had been well recognised worldwide nowadays due to the 
increase in the prevalence of the disease. The pathogenesis of the disease raised many 
questions regarding the potential mechanisms underlying the pathophysiology [96]. Several 
mechanisms have also been proposed. However, none of them were able to explain why the 
jawbone is the exclusive target [97]. Microbial infection in the pathogenesis of MRONJ is 
debatable and not fully elucidated with few publications referring to the importance of 
infection through actinomyces as a component in the multifactorial disease [17, 29, 98]. 
 
4.1.1.1 Pathological findings 
Most histopathological findings in our study show a necrotic bone pattern with 
inflammatory cell infiltration. Around three-fourths of the samples show bacterial 
colonization and one-third indicates filamentous form rod. These findings of the bone samples 
in our study were similar to previous studies [99]. Inflammation patterns with bacterial 
accumulation in the pathological reports support the infectious hypothesis and value a 
bacterial study. Actinomyces-like bacteria were found in this study in great numbers. 
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4.1.2 Microbial identification 
We did not find many microorganisms reports of MRONJ in bone samples in previous 
studies. Sedghizadeh et al. in 2008 first [79] examined 4 samples under SEM and found 
bacterial morphotypes including fusobacterium, bacillus, actinomyces, staphylococcus, 
streptococcus, selenomonas, candida, and treponemes or spirochetes. 
2012, Ji. et al. [29] performed a cohort study with 20 samples of MRONJ patients 
comparing antibiotics effect on bacterial finding. They described abundance of Firmicutes 
phylum (Streptococcus spp.) in patients that were treated with antibiotics. Wei. et al [30] 
likewise carried out molecular profiling on 6 MRONJ bone samples. Streptococcus, 
Eubacterium and Pseudoramibacter were reported as leading microorganisms. In 2014, 
Pushalkar et al [34] performed a cohort study on molecular profiling with 15 MRONJ samples 
of Parvimonas, Peptostreptococcus, Fusobacterium, Eubacterium, Dialister and Gemella. All 
previous studies had the same limitations of small subject sizes. 
To our knowledge, this study is the first report with more than 30 MRONJ bone 
samples including 136 bone samples from 2003-2015. 69 species were found (appendix 3). It 
shows the variety of geniuses. 
Most of the oral bacteria were found in this study. It indicated mixed flora of the oral 
cavity with (30.1%) Actinomyces spp (21.3%), Streptococcus spp (16.9%), and Enterobacter 
group (15.4%) being the most common microorganisms. Followed by Candida spp, Prevotella 
spp, Bacteroides spp and Enterococcus spp. These finding show a predominance of facultative 
anaerobe bacteria in our MRONJ lesion. 
Some phylotypes of microorganism were unique to MRONJ more than other non-
MRONJ infections in previous studies (Streptococcus, Eubacterium and Pseudoramibacter) 
[30]. Differrent from previous studies, there was the absence of Eubacterium spp. (rigid cell 
wall bacterial type) in this study. 
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 These results confirm that microorganisms accumulate in the MRONJ lesions. We 
hope that these findings will benefit oral and maxillofacial surgeons, give information about 
microbiological aspects of MRONJ and may help to adjust antibiotic application, antiseptic 
techniques and surgical approaches in MRONJ patients. 
 
4.1.2.1 Microbiological comparison of findings in subgroups 
This study showed various bacterial findings in MRONJ subgroups. It showed not 
much difference in comparing MRONJ patients with and without chemotherapy, except that 
more species were found in the chemo group. On the other hand, patients with smoking habits 
show different results compared to non-smokers. The culture results show twice as much 
Candida species, Streptococcus species and Neisseria species in smoking group when 
compared to non-smoking group. 
Chemotherapy treatment is a systemic factor that impacts the whole body. Other 
systemic subgroups such as diabetes and steroid intake also did not show a significant 
difference. From this finding, it could be implied that local factors had more influence than 
systemic ones. 
Regarding the analysis of subgroups further studies with more specific control of 
subjects and other factors. The difference in microorganisms’ findings could lead to an 
alternative antibiotic regimens treating MRONJ in some patients. 
 
4.1.3 Actinomyces findings 
Actinomyces species were present in most of the times in previous studies of MRONJ 
[29, 70, 80, 88, 89]. MRONJ had a former name of “Actinomyces-osteonecrosis of the jaw” 
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with high prevalence of actinomyces infection [92]. From the results of this thesis, we had 
21.3% of population positive actinomyces culture. It was proven that actinomyces were 
highly prevalent in MRONJ patients which were consistent with a previous report on MRONJ 
bone samples [88, 89, 90, 91]. 
Actinomyces are hard to be cultured in vitro, also the transport to the lab could result 
in the damage of the specimen. Many actinomyces species die during culturing and their 
growth is inhibited by the presence of other microorganisms. However, DNA from dead 
organisms can still be detected by PCR methods [93]. 
Microbiological cultures were used as a traditional technique to identify actinomyces 
from bone samples. Anaerobic culturing was done in all 136 samples. However, these results 
were confirmed by PCR for 83 bone samples. The positive PCR results of the bone samples 
that were negative to culture (39 from 83 samples = 46.98 %) were attributed to the high 
sensitivity of the PCR compared to culture methods. These results show that PCR targeting 
the 16S rRNA region can be used to detect actinomyces in MRONJ bone samples. 
From these results, we confirmed that PCR using 16S rRNA was useful in identifying 
actinomyces directly from bone samples. PCR targeting the 16S rRNA gene of the 
actinomyces is highly conserved within species of the same genus and is thus considered the 
new standard for classification and identification of bacteria as well as a reliable method for 
the distinction of species that are difficult to cultivate [100, 101]. PCR is superior to 
microbiological cultures in diagnosis of oral actinomyces as being highly sensitive and 
rapidly detecting actinomyces either dead or alive. Another advantage is that it quantifies 
DNA rather than viable organisms. However, culturing methods cannot detect non-viable 
bacteria [93]. 
In this study, we have confirmed the presence of microorganism especially 
actinomyces species in the bone samples but it is not clearly known whether osteonecrosis 
occurs before the infection of the necrotic lesion or if the infected lesion undergoes 
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osteonecrosis [102]. There are some evidences showing that infection is necessary for 
osteonecrosis with formation of a bacterial biofilm in the lesion [97, 103, 104] as the oral 
cavity is occupied by hundreds of bacterial species existing in the biofilm. When the patient 
immunity is decreased, those microorganisms show opportunistic infection such as 
actinomyces which are dominant pathogenic microorganisms detected at MRONJ by 
histopathological studies [99].  
 
4.2 Patient characteristic, disease presentation, risk and initiation 
factors 
4.2.1 Age, gender and underlying disease 
Females had a prevalence to the disease compared to males. Advanced age and 
malignancy also have been mentioned, particularly in those with breast and prostate cancer 
[105]. In this study, we had 61% female patients with a mean age of 70.1 years. Around 90% 
of the patients had cancer as a primary disease and were therefore being treated with 
antiresorptive drugs. These results confirmed the information from previous studies. 
However, we believe that these findings are influenced by the target group of 
antiresorptive drugs. Since the target-groups of antiresorptives are of advanced age and are 
predominately female. Besides, some studies recognized no statistically significant correlation 
between aging and MRONJ [106]. 
 
4.2.2 Comorbidities 
Diabetes, smoking, chemotherapy and immune based disease (rheumatoid) were 
mentioned as relative risk factors. Correlations between MRONJ and other comorbidities such 
as chemotherapy and body radiation were also mentioned [106, 107]. In this study the sample 
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of population had diabetes mellitus (19.1%), chemotherapy (58.8%), and body radiation 
(44.9%), whereby 38 patients had smoking habits (27.9%) and 33 received steroids treatment 
(24.3). 
It is known that elderly patients with comorbidities have a closer correlation to 
develop MRONJ. These comorbidities affect i) bone remodelling by microvascular ischemia 
and compromise wound healing as well as ii) impaired osteoblastic differentiation and 
function plus iii) induce additional immunosuppressive and antiangiogenic effects [108, 109]. 
In particular, smoking creates an environmental change in the oral cavity, which lowers the 
local immunity while Diabetes deters the cellular immune system. Therefore, we suspect that 
both factors have a role in the development MRONJ. 
 
4.2.3 Preceding events 
Tooth extraction and surgical trauma are noted as preceding events [52, 53, 106]. It 
has been reported that there are up to 60% MRONJ cases occurred after tooth extractions. 
Still, spontaneous’ MRONJ also has 25%. In this study, dental extractions were involved 
53.7% with lesions and 11.8% of the patients received other dentoalveolar surgeries, equally 
11.8% received periodontal treatment and 4.4% developed denture pressure sores. Roughly 
18.4% reported no intervention in the lesion area. 
Although no consensus has been reached regarding the mechanism of MRONJ, in the 
present study, MRONJ developed either spontaneously or after dentoalveolar reasons such as 
tooth extractions, periodontal disease and denture pressure sore trauma. 
Some studies proved that tooth extractions and dentoalveolar surgical procedures aim 
treating and curing local infections can even lead to a decreased risk for the development of 
MRONJ [62, 110]. Local infections were treated and overcome by the removal of infected 
teeth and suspicious bone lesions, by antibiotic treatment and mucosal coverage of the 
48 
 
 
extraction wounds, thereby protecting the extraction sockets from bacterial ingrowth after 
extraction [111]. 
 
4.2.4 Antiresorptive drugs 
Antiresorptive agents were regarded as a major risk factor for the development of 
MRONJ lesions. This study has corroborated that MRONJ is more frequent in subjects with 
intravenous bisphosphonates than in oral regimen [112]. Zoledronate was the most consumed 
and also the highest potency intravenous bisphosphonate (Figure 2). 80% of our population 
receive zolendronate or a combination. The cumulative risk of developing MRONJ was 
significantly increased in patients receiving zoledronic acid [117]. However, our result shows 
that MRONJ can also occur when denosumab is subjected subcutaneously. 
 
4.2.5 Disease presentation and Localisation 
The disease presentation was described in diagnosis and classification criteria. The 
classic clinical presentation of MRONJ is bone exposure with signs of infection, swelling and 
a purulent discharge [105]. In this study, the symptoms of inflammation, pain and exposed 
bone were present in the major part of the population. Signs of infection were also noted in 
previous reports. We believe infectious process is playing a major role in MRONJ as we will 
discuss in the following sections. 
Results of this study show that the majority of cases were in the stage II classification 
which is comparable to findings in other studies [113, 114]. MRONJ lesions occurred in the 
mandible (73.5%) twice as much as in the maxilla (31.5%) which was also in accordance with 
previous studies [50, 61]. 
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4.2.6 Prevention and Prophylaxis 
AAOMS position paper 2014 [4] has recommended a consultation with an appropriate 
dental professional before initiating an antiresorptive or antiangiogenic drug therapy.  
Dimopoulos et al [118] and Vandone et al [119] found a statistically significant 
decrease in the incidence of osteonecrosis in patients who received preventive dental care 
before initiating drug treatment. There is a reasonable support that not only a reduced 
incidence of ONJ, but also increases the benefit that all patients receive optimum oral health 
from early screening and appropriate dental care [120, 121, 122, 123]. 
Only 4 of the 136 MRONJ cases proved visited dentist or oral maxillofacial surgeon 
before antiresorptive therapy. This number shows a lack of MRONJ awareness among 
medication providers. One of our thesis objectives is to point out the infection aspect of 
MRONJ. As one of the most important factors, local infection should be eradicated before 
antiresortive therapy. 
To examine all risk factors, it is beneficial in most cases when encountered with a new 
disease. MRONJ is special in particular because a decade after the pathophysiology and even 
terminology are still indefinite. Risk factors and all the relevant factors may not cause 
MRONJ themselves. However, keeping and updating this information will benefit in risk 
assessment process in treatment and prevention strategies. 
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4.3 Limitation 
The limitations of this study are that: 
 no control group of untreated with antibiotic or treated with antibiotic 
without MRONJ patients was considered. 
 no non-MRONJ patients were characterized for bacterial species. 
 no appropriated statistic comparison in subgroup analysis. 
 the number of patients were reduced from 209 to 136 due to the 
incomplete records or absence of histopathological, microbiological or 
PCR diagnosis. 
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5 CONCLUSION 
MRONJ can reduce patient's quality of life and may produce a significant morbidity 
due to impairment of chewing, swallowing and speaking as well as deterioration of facial 
aesthetics. Thus, it is of tremendous importance to treat those patients to adequately eliminate 
pain, control infection of soft and hard tissue and eradicate bone exposure [115]. Information 
might be useful in assisting surgeons in making suitable decisions on the treatment modality 
of the disease based on the hypothesis that infection maybe the most important factor 
negatively influencing the onset and progression of MRONJ. 
The pathogenesis of MRONJ had raised many questions regarding the potential 
mechanisms underlying the pathophysiology with special attention to the role of microbial 
infection. Facultative anaerobe bacteria governing by Actinomyces, Streptococcus, and 
Enterobacter group were found as the highest frequency of microorganisms in 136 bone 
culture samples. The PCR results showed that Actinomyces were the most frequent 
microorganisms in the disease. However, this does not certainly lead to the pathogenic 
disease. PCR was found to be the most reliable method in the detection of these 
microorganisms. 
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6 SUMMARY 
 We hypothesized that local infection plays a critical role in the pathogenesis of 
medication-related osteonecrosis of the jaw (MRONJ). Recent developments in molecular 
methods have revolutionized new approaches for the rapid detection of microorganisms 
including those difficult to culture. The aim of our study is to identify the bacterial profiles in 
MRONJ by microbiological culture and polymerase chain reactions (PCR). A retrospective 
analysis was performed on MRONJ patients from 2003 to 2015 where the bacterial profile 
from MRONJ bone samples was determined using microbiological culture and PCR. One 
hundred and thirty six patients fulfilled the inclusion criteria with mean age of 70.1 ± 8.83 
years. The mandible was more commonly affected than the maxilla. Tooth extraction was the 
frequent triggering factor. Breast cancer was the primary cause for administration and 
intravenous bisphosphonates were the most commonly administrated antiresorptive drugs. 
The majority of patients were classified as stage 2. Posterior teeth were most commonly 
affected. Based on bone culture results, the most common microorganisms were both 
actinomyces and mixed oral flora. PCR confirmed the presence of undetected actinomyces in 
83 patients. The data resulting from this study suggest that PCR might be an innovative 
method for detection of microorganisms difficult to culture better than using traditional 
microbiological techniques. 
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ZUSAMMENFASUNG 
Nach neuesten Erkenntnissen spielen lokale Infektionen bei der Pathogenese der 
Medikamenten-assoziierten Osteonekrose der Kiefer (MRONJ) eine entscheidende Rolle. Mit 
der Entstehung und mit der Manifestation von Infektionen sind Alterationen des 
Keimspektrums von der physiologischen Mundflora hin zur Etablierung einzelner 
Keimspezies zu erkennen. Die Verbesserung der Sensivität von molekular-diagnostischen 
Modalitäten eröffnet neue Optionen für den selektiven Nachweis von Mikroorganismen, die 
im Zuge einer derartigen Verschiebung vermehrt auftreten. 
Das Ziel dieser Studie war es, die Bakterienprofile, die beim Krankheitsbild MRONJ 
vorliegen, durch mikrobiologische Kultur und Polymerase Kettenreaktionen (PCR) zu 
identifizieren und charakterisieren. 
Es wurde in einem retrospektiven Studiendesign das Erregerprofil von Patienten 
bestimmt, die an einer MRONJ erkrankt waren und sich im Zeitraum von 2003 bis 2015 in 
der Klinik und Poliklinik für Mund-, Kiefer- und Gesichtschirurgie der LMU München in 
Behandlung befanden. Hierfür wurden an den gewonnenen Knochenbiopsien durch 
mikrobiologische Kultur und PCR das Vorkommen von bestimmten Bakterienarten 
untersucht. 
Die untersuchte Kohorte umfasste 136 Patienten in einem Durchschnittsalter von 70,1 
± 8,83 Jahren. Der Unterkiefer war bei diesen Patienten häufiger betroffen als der Oberkiefer. 
Zahnextraktionen in Kombination mit in der Vergangenheit stattgehabter intravenöser 
Applikation von Bisphosphonaten gingen der MRONJ häufig als induzierende Faktoren 
voraus.  Bisphosphonate wurden hierbei  häufig therapeutisch bei Patienten eingesetzt, die 
unter einem skelettal metastasierten Mammakarzinom litten. Der Großteil der Patienten wurde 
in das Stadium 2 (AAOMS 2014) eingestuft.  
54 
 
 
Basierend auf den mikro- und molekularbiologischen Untersuchungen wurden 
Actinomyzeten als am häufigsten vorkommende Bakterien identifiziert. Dabei komplettierte 
die PCR, die üblicherweise eingesetzten Nachweismethodiken. Im Vergleich zu diesen konnte 
durch den Einsatz der PCR bei 83 Patienten eine Besiedelung mit Actinomyceten 
nachgewiesen werden, die in der mikrobiologischen Kultur nicht erkannt wurden.  
Die PCR stellt eine die üblichen mikrobiologischen Untersuchungen komplettierende 
Methode zum selektiven Nachweis von Mikroorganismen dar, die aufgrund ihrer geringen 
Anzahl und schwierigen Kultivierungsvoraussetzungen mit herkömmlicher mikrobiologischer 
Diagnostik nicht nachzuweisen sein können. 
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9 APPENDIX 
Appendix 1: Common Antiresorptive agents [124] 
Antiresorptive agents 
Brand Name Generic Name Dosage Manufacture 
Approved 
Indications 
(Date) 
Oral Formulations 
Actonel 
Risedronate 
sodium 
5-, 35-, 75- and 150-
milligram tablets 
Warner Chilcott, 
Dublin 
Worldwide 
(1998) 
To prevent and treat osteoporosis in post-menopausal women 
To prevent and treat osteoporosis in men and women caused by 
steroid treatment 
To treat Paget disease of bone in men and women 
Atelvia 
Risedronate 
sodium 
35-mg tablet 
(once/weekly) 
Warner Chilcott 
Worldwide 
(2010) 
To treat osteoporosis in post-menopausal women 
Bonefos 
Clodronate 
disodium 
400-mg capsules 
(Canada), 800-mg 
tablets (Europe) 
Bayer, Toronto Canada (1992) To prevent and treat osteoporosis in post-menopausal women 
Bayer, Berlin Europe (1985) 
To treat hypercalcemia and osteolysis due to malignancy 
To reduce occurrence of bone metastasis in primary breast cancer 
Boniva 
Ibandronate 
sodium 
2.5-mg tablet once 
daily, 150-mg 
Genentech, South 
San Francisco, 
Calif. 
United States 
(2003) 
To prevent and treat osteoporosis in post-menopausal women 
Bonviva 
Ibandronate 
sodium 
150-mg tablet once 
monthly 
Genentech Europe (2004) To prevent and treat osteoporosis in post-menopausal women 
Didronel 
Etidronate 
sodium 
400-mg tablets Warner Chilcott 
United States 
(1983), Europe 
To treat Paget disease of bone 
To prevent and treat heterotopic ossification in people who have 
undergone total hip replacement or in people who have and injury to 
the spinal cord 
Etidronate Etidronate 200-, 400-mg tablets 
Mylan 
Pharmaceuticals, 
Morgantown, W.V. 
United States 
(2003), 
Note: off-label use to prevent and treat osteoporosis caused by 
steroid treatment 
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Fosamax 
Alendronate 
sodium 
5-, 10-, 35-, 40-and 70-
mg tablets 
Merck & Co., 
Whitehouse Station, 
N.J. 
United States 
(1995) 
To prevent and treat osteoporosis in post-menopausal women and 
increase bone mass in men with osteoporosis 
Europe (1995) 
To treat Paget disease of bone 
To prevent and treat osteoporosis in men and women caused by 
steroid treatment 
Fosamax 
Plus D 
Alendronate 
sodium/ 
cholecalciferol 
70-mg tablet or 70-mg 
oral solution 
Merck & Co. 
United States 
(2005), To prevent and treat osteoporosis in post-menopausal women and 
increase bone mass in men with osteoporosis 
Europe (2005) 
Generic 
alendronate 
Alendronate 
sodium 
5-, 10-, 35-, 40- and 70-
mg  tablets 
Various 
Worldwide 
(2008) 
To prevent and treat osteoporosis in post-menopausal women and 
increase bone mass in men with osteoporosis 
To treat Paget disease of bone 
To prevent and treat osteoporosis in men and women caused by 
steroid treatment 
Skelid 
Tiludronate 
disodium 
240-mg tablets 
(equivalenct to 200-mg 
base) 
Sanofi-Aventis, 
Bridgewater, N.J. 
United States 
(1997) 
To treat Paget disease of bone 
Aredia 
Pamidronate 
disodium 
30-, 90-mg vials 
Novartis 
Phamaceuticals, 
East Hanover, N.J. 
Worldwide 
(2001) 
To treat moderate or severe hypercalcemia with malignancy, with or 
without bone metastases 
To treat osteolytic bone metastasis of breast cancer and osteolytic 
lesion of multiple myeloma in conjunction with standard 
antineoplastic therapy 
To treat Paget disease of bone 
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Antiresorptive agents 
Brand Name Generic Name Dosage Manufacture 
Approved 
Indications 
(Date) 
Parenteral Formulation 
Bonefos 
Clodronate 
disodium 
60-mg/ 1 millilitre, 
1,500-mg single dose 
Bayer, Toronto Canada (1992) To treat Paget disease of bone 
Bayer, Schering Europe (1985) 
To treat  hypercalcemia due to metastatic bone disease, multiple 
myeloma and parathyroid carcinoma 
Boniva IV 
Ibandronate 
sodium 
3mg/3 ml single use Genetech 
United States 
(2006), Europe 
(2006) 
To treat osteoporosis in postmenopausal women 
Prolia Denosumab 
60-mg subcutaneous 
injection every six 
month 
Amgen, Thousand 
Oaks, Calif. 
United States 
(2010), Europe 
(2010) 
To prevent skeletally related events in patients with bone metastases 
from solid tumors 
XGEVA Denosumab 
120-mg in 1.7-mL 
subcutaneous injection 
every four weeks 
Amgen 
United States 
To prevent skeletally related events in patients with bone metastases 
from solid tumors -2010 
Reclast 
(US.) 
Zoledronic 
acid 
5-mg in a 100-mL 
ready-to-infuse solution 
Novartis 
Phamaceuticals 
United States 
(Reclast) (2007) 
To prevent and treat osteoporosis in post-menopausal women and 
increase bone mass in men with osteoporosis 
Aclasta Worldwide 
To prevent and treat glucocorticoid-induced osteoporosis in patients 
expected to receive glucocorticoid therapy for at least 12 months 
(Europe) (Aclasta) (2005) To treat Paget disease of bone 
Zometa 
Zoledronic 
acid 
4-mg/5-mL single-dose 
vials 
Novartis 
Phamaceuticals 
Worldwide 
(2001) 
To treat hypercalcemia of malignancy 
To reduce delay bone complication due to multiple myeloma and 
bone metastases from solid tumors, in conjunction with anticancer 
medications 
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Appendix 2: Patient history parameter List 
Age (years) 
Gender:  Male / Female 
Primary cause of antiresorptive agents 
- Breast cancer 
- Prostate cancer 
- Multiple myeloma 
- Osteoporosis 
- Lung cancer 
- Other (Colon, Systemic, Mastocytosis, Renal, Bladder, Thyroid, Endometrium) 
 
Comorbidities 
- Diabetes Mellitus 
- Cardiovascular disease 
- Chemotherapy 
- Irradiation 
- Steroid intake 
- Antiangiogenetic drugs 
- Smoking 
 
Type of Antiresorptive drug (ARD) 
Bisphosphonate: 
- Zoledronate 
- Pamidronate 
- Ibandronate 
- Combination 
- Denosumab 
-  
Route of adminstration 
- Intravenous 
- Oral 
- Subcutaneous 
 
Staging of MRONJ:  stage 0-3 
Clinical presentation 
- Pain 
- Exposed bone 
- Inflammation  
- Disturbance in wound healing 
- Swelling  
- Pus presentation  
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- Fistula 
- Pathological fracture (Mandible) 
- Sinus involvement (Maxilla) 
 
Location: tooth area 
- Mandible 
- Maxilla 
- Both 
 
Triggering events 
- Extractions 
- Other Dentoalveolar surgery 
- Denture sore 
- Periodontal lesion&treatment 
- Spontaneous 
 
Prevention 
- Dentist visited before antiresorptive medication 
- Stop antiresorptive after ONJ diagnosis 
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Appendix 3: List of finding bacteria 
 
Species list 
1 Actinomyces species 36 Klebsiella pneuminiae 
2 Actinomyces odontolyticus 37 Klebsiella oxytoca 
3 Actinomyces naeslundii 38 Koagulase neg. Staphylokokken 
4 Aggregatibacter aphrophilus 39 Lactobacillus species 
5 Atopobium species 40 Morganella morganii 
6 Anaerobe mischflora 41 Mundflora 
7 Anaerobe mundflora 42 Neisseria species 
8 Bacteroides thetaiofaomicron 43 Neisseria mucosa 
9 Bacteroides fragillis 44 Olsenella uli 
10 Bacteroides uniformis 45 Parvimonas micra 
11 Bacteroides stercoris 46 Parabacteroides distasonis 
12 Biophila wadsnorthia 47 Peptostreptococcus species 
13 Clostridium species 48 Prevotella species 
14 Candida species 49 Prevotella intermedia 
15 Candida albicans 50 Prevotella buccae 
16 Candida krusei 51 Prevotella mellaninogenica 
17 Candida grabrata 52 Prevotella nigrescens 
18 Candida tropicalis 53 Porphyromonas species 
19 Campyrobacter rectus 54 Porphyromonas asaccharolyticus 
20 Citrobacter freundii 55 Porphyromonas gingivalis 
21 Corynebacterium species 56 Propionibacterium propionicum 
22 Eikenella corrodens 57 Propionibacterium acnes 
23 Enterobacter aerogenes 58 Providencia vettgeri 
24 Enterobacter cloacae 59 Proteus vulgaris 
25 Enterobacter cloacae complex 60 Serratia marcescens 
26 Enterococcus avium 61 Serratia ureilytica 
27 Enterococcus faecalis 62 Streptococcus anginosus 
28 Escherichia coli 63 Streptococcus parasanguinius 
29 Fusobacterium mortiferum 64 Streptococcus gordonii 
30 Fusobacterium necrophorum 65 Streptococcus cohnii 
31 Fusobacterium nucleatum 66 Vergruenende streptokokken 
32 Haemophilus parainfluenzae 67 Veillonella species 
33 Haemophilus influenza 68 Veillonella parvula 
34 Hafnia alvei 69 Veillonella denticariosi 
35 Haemolysierende Streptococcus gr.F 
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